Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas

American Journal of Pathology

Volumn 148, Issue 4, 1996, Pages 1139-1152

  Mäenpää, Anna ^a,b   Junnikkala, Sami ^a   Hakulinen, Juha ^a   Timonen, Tuomo ^a   Meri, Seppo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Department of Pathology ^*  (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; CONTROLLED STUDY; CYTOLYSIS; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; NORTHERN BLOTTING; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GLIOMA; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 0029869664     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Barba D, Saris SC, Holder C, Rosenberger SA, Oldfield EH: Intratumoral LAK cell, and interleukin-2 therapy of human gliomas. J Neurosurg 1989, 70:175-182
2. Ingram M, Shelden CH, Jacques S, Skillen RG, Bradley WG, Techy GB, Freshwater DB, Abts RM, Rand RW. Preliminary clinical trial of immunotherapy for malignant glioma. J Biol Response Modif 1987, 6 489-498
3. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma J Neurosurg 1986, 64:743-749
4. Merchant RE, Merchant LH, Cook SHS, McVicar DW, Young HF: Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurg 1988, 23:725-732
5. Yoshida S, Tanaka R, Takai N, Ono K: Local administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with malignant brain tumors Cancer Res 1988, 48:5011-5016
6. Morgan BP, Meri S: Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994, 15:369-396
7. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF: Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system J Immunol 1982, 129:184-189
8. Fearon DT: Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membranes. Proc Natl Acad Sci USA 1979, 76 5867-5871
9. Seya T, Turner JR, Atkinson JP: Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med 1986, 163:837-855
10. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, Waldmann H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells J Exp Med 1989, 170:637-654
11. Men S. Protectin (CD59): complement lysis inhibitor and prototype domain in a new protein superfamily. Immunologist 1994, 149-155
12. Men S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H: Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers Immunology 1990, 71:1-9
13. Rollins SA, Zhao J, Ninomiya H, Sims PJ. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 1991, 146:2345-2351
14. Junnikkala S, Hakulinen J, Men S: Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur J Immunol 1994, 24:611-615
15. Jokiranta TS, Men S: Biotinylation of monoclonal antibodies prevents their ability to activate the classical pathway of complement. J Immunol 1993, 151:2124-2131
16. Koretz K, Brüderlein S, Henne C, Moller P: Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium Br J Cancer 1993, 68: 926-931
17. Bjørge L, Vedeler CA, Ulvestad E, Matre R. Expression and function of CD59 on colonie adenocarcinoma cells Eur J Immunol 1994, 24 1597-1603
18. Hakulinen J, Meri S: Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest 1994, 71:820-827
19. Jääskeläinen J, Kalliomäki P, Paetau A, Timonen T: Effect of LAK cells against three-dimensional tumor tissue. J Immunol 1989, 142:1036-1045
20. Meri S, Mattila P, Renkonen R. Regulation of CD59 expression on the human endothelial cell line EA.hy 926. Eur J Immunol 1993, 23.2511-2516
21. Markwell MA, Haas SM, Tolbert NE, Bieber LL: Protein determination in membrane and lipoprotein samples: manual and automated procedures. In Methods in Enzymology. Edited by JM Lowenstein. New York, Academic Press, 1981, p 293-303
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159
23. Shinoura N, Heffelfinger SC, Miller M, Shamraj OI, Miura NC, Larson JJ, DeTribolet N, Warnick RE, Tew JJ, Menon AG: RNA expression of complement regulatory proteins in human brain tumors Cancer Lett 1994, 86:143-149
24. Vedeler C, Ulvestad E, Bjørge L, Conti G, Williams K, Mørk S, Matre R: The expression of CD59 in normal human nervous tissue. Immunology 1994, 82:542-547
25. Gordon DL, Sadlon T, Hefford C, Adrian D: Expression of CD59, a regulator of the membrane attack complex of complement, on human astrocytes. Mol Brain Res 1993, 18:335-338
26. Men S, Waldmann H, Lachmann PJ: Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 1991, 65: 532-537
27. Johnstone RW, Loveland BE, McKenzie IFC: Identification and quantification of complement regulator CD46 on normal human tissues. Immunology 1993, 79:341-347
28. Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects Biochem J 1989, 264:1-14
29. Jenne DE, Tschopp J: Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 1992, 17:154-159
30. Danik M, Chabot J-G, Mercier C, Benabid A-L, Chauvin C, Quirion R, Suh M: Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death Proc Natl Acad Sci USA 1991, 88:8577-8581
31. Gasque P, Julen N, Ischenko A, Picot C, Mauger C, Chauzy C, Ripoche J, Fontaine M: Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 1992, 149 1381-1387
32. Gasque P, Ischenko A, Legoedec J, Mauger C, Schouft M-T, Fontaine M. Expression of the complement classical pathway by human glioma in culture. J Biol Chem 1993, 268:25068-25074